Acute cholestatic hepatitis associated with celecoxib

Annals of Pharmacotherapy

Volumn 36, Issue 12, 2002, Pages 1887-1889

  Grieco, Antonio ^a   Miele, Luca ^a   Giorgi, Andrea ^a   Civello, Ignazio M ^b   Gasbarrini, Giovanni ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b NONE

Author keywords

Celecoxib; Hepatotoxicity

Indexed keywords

ANTIBIOTIC AGENT; CELECOXIB; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ACUTE DISEASE; ADULT; ARTICLE; CASE REPORT; CHOLECYSTECTOMY; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; DISEASE COURSE; ECHOGRAPHY; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; JAUNDICE; KNEE INJURY; LABORATORY TEST; MALE; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; CHEMICALLY INDUCED DISORDER; CHOLESTASIS; HYPERBILIRUBINEMIA; TOXIC HEPATITIS;

ACUTE DISEASE; ADULT; ALANINE TRANSAMINASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTATE AMINOTRANSFERASES; CHOLESTASIS; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS, TOXIC; HUMANS; HYPERBILIRUBINEMIA; MALE; PYRAZOLES; SULFONAMIDES;

EID: 0036896238     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C110     Document Type: Article

References (24)

1. Zimmermann HJ, Ishak KG. General aspects of drug-induced liver disease. Gastroenterol Clin North Am 1995;24:739-58.
2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T. Whelton A, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2 p following 1528.
4. Gasbarrini G, Grieco A, Miele L, Mingrone G, Capristo E, Gasbarrini A, et al. Drug induced liver disease. Ann Ital Med Int 2001;16(suppl 4):1S-80S.
5. Lewis JH. Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin Pharm 1984;3:128-38.
6. Boelsterli UA, Zimmerman HJ, Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal anti-inflammatory drugs: Molecular mechanisms and pathology. Crit Rev Toxicol 1995;25:207-35.
7. Lerche A, Vyberg M, Kirkegaard E. Acute cholangitis and pancreatitis associated with sulindac (Clinoril). Histopathology 1987;11:647-53.
8. Banks AT, Zimmerman HJ, Ishak KG. Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the Food and Drug Administration. Hepatology 1995;22:820-7.
9. Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol 1996;91:1626-30.
10. Maddrey WC, Maurath CJ, Verburg KM, Geis GS. The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. Am J Ther 2000;7:153-8.
11. Carrillo-Jimenez R, Nurnberger M. Celecoxib-induced acute pancreatitis and hepatitis: A case report. Arch Intern Med 2000;160:553-4.
12. Galan MV, Gordon SC, Silverman AL. Celecoxib-induced cholestatic hepatitis (letter). Ann Intern Med 2001;134:254.
13. O'Beirne JP, Cairns SR. Drug points: Cholestatic hepatitis in association with celecoxib. BMJ 2001;323:23.
14. Nachimuthu S, Volfinzon L, Gopal L. Acute hepatocellular and cholestatic injury in a patient taking celecoxib. Postgrad Med J 2001;77:548-50.
15. Malka D, Pham BN, Courvalin JC, Corbic M, Pessayre D, Erlinger S. Acute hepatitis caused by alverine associated with anti-lamin A and C autoantibodies. J Hepatol. 1997;27:399-403.
16. Zenut M, Pauchard J, Lavarenne J. Recurrent liver involvement induced by alverine. Therapie 1997;52:78-9.
17. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet 1999;353:1763-4.
18. Goodman RC, Dean PJ, Radparvar A, Kitabchi AE. Glyburide-induced hepatitis. Ann Intern Med 1987;106:837-9.
19. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
20. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6.
21. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26: 664-9.
22. Aithal GP, Rawlins MD, Day CP. Clinical diagnostic scale: A useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 2000;33:949-52.
23. Lee WM. Assessing causality in drug-induced liver injury. J Hepatol 2000;33:1003-5.
24. Kaplowitz N. Drug-induced liver disorders: Implications for drug development and regulation. Drug Saf 2001;24:483-90.